# Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Source: https://onco.cc/trials/nct01436968/  
OnCo record `nct01436968` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Aglatimagene besadenovec in prostate cancer, run by Candel Therapeutics, Inc., active and no longer recruiting.

## Summary

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer is a phase 3 interventional study registered as NCT01436968 by Candel Therapeutics, Inc., with 711 participants planned, started 2011-09 and due to reach its primary completion in 2024-08. Interventions recorded: Aglatimagene besadenovec + valacyclovir, Placebo + valacyclovir. Conditions listed: Prostate Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT01436968
- Phase: 3
- Setting: A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer
- Sponsor: Candel Therapeutics, Inc.
- Enrolled: 711

## Sources

- ClinicalTrials.gov NCT01436968: https://clinicaltrials.gov/study/NCT01436968

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Aglatimagene besadenovec](https://onco.cc/drugs/aglatimagene-besadenovec/)
- companies: [Candel Therapeutics](https://onco.cc/companies/candel-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct01436968.json